Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Gracell Reports Positive Results from FasT CAR-19 Cell Gene Therapy

publication date: Sep 12, 2019

Gracell, a Suzhou-Shanghai biotech, announced positive early results of its first-in-class FasT CAR-19 investigational cell gene therapy: in 24 patients, 23 (95.8%) achieved complete remission and 21 (87.5%) showed undetectable minimal residual disease (uMRD). All of the patients had relapsed/refractory B-ALL leukemia. Gracell's FasT CAR therapy reduces preparation time of the T-cells from two weeks to one day, lowering the cost. The results were announced during the CAR-TCR Summit currently being held in Boston. More details....

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China